Cytokine adsorption in patients with acute‐on‐chronic liver failure ( CYTOHEP ): A single center, open‐label, three‐arm, randomized, controlled intervention pilot trial
Artificial Organs · 2024
DOI: 10.1111/aor.14774 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Artificial Organs, 2024. Verfasst von Asieb Sekandarzad und 7 weiteren Autor:innen. Beteiligte Einrichtung: Interdisciplinary Medical Intensive Care, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. Hauptthemen laut MEDLINE: Acute-On-Chronic Liver Failure, Bilirubin, Continuous Renal Replacement Therapy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
To investigate the efficacy of bilirubin reduction by hemoadsorption with CytoSorb® in patients with acute‐on‐chronic liver failure (ACLF) receiving continuous renal replacement therapy (CRRT).
Methods
A prospective, randomized, single‐center, open‐label, controlled pilot trial. Patients with ACLF, acute kidney injury, and serum bilirubin ≥5 mg/dL were assigned 1:1:1 to one of three study groups (CRRT with or without hemoadsorption, no CRRT). In the hemoadsorption group, the CytoSorb adsorber was incorporated into the CRRT system, replaced after 12, 24, and 48 h, and removed after 72 h. The primary endpoint was the serum bilirubin level after 72 h.
Results
CYTOHEP was terminated early due to difficulties in recruiting patients and ethical concerns. Three of 9 patients (33%) were treated in each group. Comparing the three groups, mean bilirubin levels after 72 h were lower by −8.0 mg/dL in the “CRRT with hemoadsorption” group compared to “CRRT without hemoadsorption” (95% CI, −21.3 to 5.3 mg/dL; p = 0.17). The corresponding mean difference between “CRRT without hemoadsorption” and “no CRRT” was −1.4 mg/dL (95% CI, −14.2 to 11.5 mg/dL; p = 0.78). Comparing “CRRT with hemoadsorption” and “no CRRT,” it was −9.4 mg/dL (95% CI, −20.8 to 2.1 mg/dL; p = 0.0854). Only 1/9 patients (11%, “no CRRT” group) survived day 30 after study inclusion but died on day 89. IL‐6, liver function parameters, and clinical scores were similar between the study groups.
Conclusions
CYTOHEP failed to demonstrate that extracorporeal hemoadsorption combined with CRRT can reduce serum bilirubin in ACLF patients with acute kidney failure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Interdisciplinary Medical Intensive Care, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
- Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center - University of Freiburg, Freiburg, Germany.
- Department of Medicine IV, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
- Department of Medicine II, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
ORCID-Profile: Dawid L Staudacher, Alexander Supady
Zitieren
APA
Sekandarzad, A., Graf, E., Prager, E. P., Luxenburger, H., Staudacher, D. L., Wengenmayer, T., Bettinger, D., & Supady, A. (2024). Cytokine adsorption in patients with acute‐on‐chronic liver failure ( CYTOHEP ): A single center, open‐label, three‐arm, randomized, controlled intervention pilot trial. Artificial Organs. https://doi.org/10.1111/aor.14774
Vancouver
Sekandarzad A, Graf E, Prager EP, Luxenburger H, Staudacher DL, Wengenmayer T, et al. Cytokine adsorption in patients with acute‐on‐chronic liver failure ( CYTOHEP ): A single center, open‐label, three‐arm, randomized, controlled intervention pilot trial. Artificial Organs. 2024. doi:10.1111/aor.14774
BibTeX
@article{Sekandarzad2024,
author = {Sekandarzad, Asieb and Graf, Erika and Prager, Eric Peter and Luxenburger, Hendrik and Staudacher, Dawid L and Wengenmayer, Tobias and Bettinger, Dominik and Supady, Alexander},
title = {Cytokine adsorption in patients with acute‐on‐chronic liver failure ( CYTOHEP ): A single center, open‐label, three‐arm, randomized, controlled intervention pilot trial},
journal = {Artificial Organs},
year = {2024},
doi = {10.1111/aor.14774}
}
EUVIMED